Krystal Biotech updates key Vyjuvek filing, shares trade firmly on Nasdaq
23.06.2026 - 15:00:13 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:51.
Krystal Biotech Inc. (US5012681064) continues to build out its Vyjuvek franchise after recent regulatory milestones, with the Nasdaq listing keeping the stock on the radar of US healthcare investors. The company has focused current efforts on expanding patient access in the US and Europe, according to its recent filings and presentations.
What recent reports highlight
Analysts at several US houses describe Krystal Biotech as a commercial-stage gene therapy company with a growing base of revenue from Vyjuvek, its treatment for dystrophic epidermolysis bullosa, and a pipeline of additional dermatology programs in development.MarketScreener company overview Recent commentary notes that the company is targeting rare diseases where competition is limited and pricing remains high, which underpins revenue potential in the medium term.
Market data providers show Krystal Biotech with a multi-billion-dollar market capitalization and a share price in the low-to-mid three-digit US-dollar range, reflecting investors’ expectations for sustained Vyjuvek uptake and further indication expansions.Stash share data on KRYS The stock trades on the Nasdaq Global Select Market under the ticker KRYS, giving it visibility in the US biotech space alongside peers working on gene therapies.
How Wall Street values the stock
Consensus data compiled by independent platforms indicate that most analysts covering Krystal Biotech rate the shares positively, with a majority of recommendations in the Buy or Outperform range and only a small number of Hold ratings.TipRanks consensus overview Target prices commonly sit above the current trading level, signaling that many on Wall Street see further upside if execution on Vyjuvek and the broader pipeline stays on track.
In their models, analysts emphasize the importance of continued patient onboarding for Vyjuvek, reimbursement dynamics in the United States and Europe, and progress of late-stage pipeline assets addressing additional dermatologic indications.Morningstar snapshot for KRYS For risk, they point to the usual uncertainties around gene therapy durability, regulatory expectations, and potential competition from other advanced therapies over time.
All news and analysis on the Krystal Biotech shares
Further background, regulatory updates and market reactions to Krystal Biotech can be found in the dedicated topic section and on the company’s Investor Relations page.
The product behind the stock
Krystal Biotech generates its initial commercial revenue from Vyjuvek, a topical gene therapy designed for patients with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The therapy uses a viral vector to deliver functional copies of the COL7A1 gene directly to the skin, aiming to support wound healing and reduce blistering episodes over time.
Where the stock trades today
The Krystal Biotech shares (US5012681064) trade on the Nasdaq Global Select Market at 343.43 US dollars as of 2026-06-22, 20:00, according to recent closing data.
Krystal Biotech at a glance
- Company: Krystal Biotech, Inc.
- ISIN: US5012681064
- WKN: A2JMW3
- Ticker: KRYS
- Trading venue: Nasdaq
- Price (as of 2026-06-22, 20:00): 343.43 USD
- Market cap: 9.8 billion USD (as of 2026-06-22)
- Sector / industry: Biotechnology / Gene Therapy
- Index membership: none of the major headline indices such as S&P 500 or Nasdaq-100
- Next earnings date: 2026-08-05
This article is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell any financial instrument. Investors should conduct their own research and consider their individual financial situation and risk tolerance before making investment decisions.
